Form 4 for HAE HAEMONETICS CORP
Accepted 2024-05-21 00:00:00 ET · period of report 2024-05-17 · accession 0001127602-24-016162 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-21 | 2024-05-17 | HAE | DArecca James | EVP, CFO | A - Grant | — | +4,439 | 17.3K | +34% | — |
| D | 2024-05-21 | 2024-05-17 | HAE | DArecca James | EVP, CFO | A - Grant | $0.00 | +9,756 | 9,756 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-17 | A | A | 4,439 | — | 17,346 | D | — | — | (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F3) This number includes unvested RSUs previously reported. |
| 2 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-05-17 | A | A | 9,756 | $0.00 | 9,756 | D | $95.73 · — to 2031-05-17 | 9,756 Common Stock | (F4) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |